| Literature DB >> 20797754 |
Jonatan Ersching1, Malva I M Hernandez, Fabrizzio S Cezarotto, Jovino D S Ferreira, Amely B Martins, William M Switzer, Zhiquan Xiang, Hildegund C J Ertl, Carlos R Zanetti, Aguinaldo R Pinto.
Abstract
Vaccines based on adenovirus (Ad) vectors are currently in development against several pathogens. However, neutralizing antibodies (NAb) to human adenovirus type 5 (AdHu5), the best-studied vector, are highly prevalent in humans worldwide. Less-prevalent adenoviruses, including human and simian serotypes, provide alternative vaccine platforms. In this study, sera from 200 Brazilian human subjects and New-World monkeys were tested for NAb titers to human serotypes AdHu5 and AdHu26 and chimpanzee-origin Ad viruses of serotype 6 (AdC6) and serotype 68 (AdC68). Seroprevalence rates of NAb in humans were 69.5% for AdHu5, 44% for AdHu26, 21% for AdC6 and 23.5% for AdC68. In addition, NAb titers to human Ad were consistently higher than those found to simian serotypes. Surprisingly, sera from some New-World monkey species were able to neutralize AdC6 and/or AdC68. A possible explanation for these findings and the implications for the development of Ad-vector vaccines are discussed in detail.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20797754 DOI： 10.1016/j.virol.2010.07.043
Source DB: PubMed Journal: Virology ISSN： 0042-6822 Impact factor: 3.616